- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- Diplomat becomes distributor of recently approved cancer drug
- FDA advisory panel to consider OTC status of NSAIDs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
LAKE FOREST, Ill. — The Food and Drug Administration has approved a generic cancer drug from Hospira.
The drug maker announced the approval of topotecan injection for treating small-cell lung cancer sensitive disease after first-line chemotherapy has failed.
The drug is a generic version of GlaxoSmithKline’s Hycamtin, which had sales of more than $140 million in 2010, according to Hospira.